

APC is a high-utility mutational biomarker that may identify subpopulations of mutant RAS/BRAF and right-sided colorectal cancer (CRC) patients who derive benefit from EGFR inhibitors (EGFRi) Ramya Thota, Timothy Yeatman, Nishant Gandhi, Mingli Yang, Michael Schell, Lance Pflieger, Andrey Loboda, Michael Nebozhyn, Andrew Elliott, Joanne Xiu, George W. Sledge Jr., Moh'd M. Khushman, Emil Lou, Sanjay Goel, Warren Jack Pledger

Intermountain Health, Murray, UT; University of South Florida, Tampa, FL; Caris Life Sciences, Phoenix, AZ; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Phenome Health, Seattle, WA; Merck Research Laboratories, Boston, MA; Merck Research Laboratories, West Point, PA; Washington University in St. Louis/Siteman Cancer Center, St. Louis, MO; University of Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Tampa General Hospital, Tampa, FL


Background

- Cetuximab (CTX) and Panitumumab (PMB) therapies directed at EGFR have been restricted to left-sided CRC harboring wildtype KRAS (KRAS^{WT}), limiting their utility.
- Approximately 50% of mCRC fail to respond to EGFRi, thus identification of predictive biomarkers is an unmet need.
- Here we evaluate a prespecified 203 gene expression score measuring cetuximab sensitivity (CTX-S) in a large, real-world population of RAS/BRAF mutant vs wild-type and in right- vs left-sided tumors.

Objectives and Methods


- CTX/PMB treated CRC samples were analyzed at Caris Life Sciences (Phoenix, AZ) with DNAbased next-generation sequencing (NGS; 592 genes, NextSeq) or whole-exome sequencing (NovaSeq) and with RNA-based wholetranscriptome sequencing (WTS, NovaSeq).
- 1097 specimens were MSS as determined by IHC of MMR proteins and/or NGS.
- Association of CTX-S with RAS/BRAF mutation and tumor sidedness was performed in MSS tumors
- Tumors with likely pathogenic mutations in KRAS, NRAS or BRAF were considered as RAS^{MUT}/BRAF^{MUT}, or RAS^{WT}/BRAF^{WT} if no mutation was detected for each gene
- Samples were stratified based on CTX-S quintiles.
- Survival on EGFRi was calculated from the initiation of EGFRi to last contact using Kaplan-Meir method.

Figure 1: Association of APC mutation status with survival on EGFRi in the context of **RAS/BRAF** mutations



Compared to wild-type, APC mutations were associated with improved survival on EGFRi in both RAS/BRAF mutant as well as RAS/BRAF wild-type tumors


Figure 2: Association of APC mutation status with survival on EGFRi in the context of tumor sidedness



Compared to wild-type, APC mutations were associated with improved survival on EGFRi in both left- and right-sided CRC


Supported by: NCI UH3CA227955 (TJY), R21CA256372 (TJY), R21CA255312 (TJY) Contact: ramya.thota@imail.org

Results



RAS/BRAF wild-type tumors. Similar benefit was not observed in CTX-treated CRC


Figure 4: Association of APC mutation status with PMB-TOT in the context of tumor sidedness



Compared to wild-type, APC mutations were associated with extended PMB-TOT in both left- and right-sided CRC. Similar benefit was not observed in CTX-treated CRC

Conclusions

- Our data suggests that the simple application of a high-utility mutational biomarker (APC), may increase the eligibility for successful EGFRi therapy in a substantial subpopulation of RAS/BRAF mt patients as well as right-sided CRC, potentially altering the standard of care.
- Further validation of this biomarker in a prospective clinical trial is warranted.



		- APC ^{LP/P} (n=109) - APC ^{WT} (n=35) HR = 0.663, p=0.037				
15	00		00	25	00	

RCRC: EGFRi-OS

PRECISION ONCOLOGY ALLIANCE $CARIS^{\circ}$